Table 3.

Case reports of teriparatide associated hypercalcemia.

Author (year)	Age, sex	Pretreatment calcium	Laboratory Data	Comments
Thiruchelvam (2014)13	65, F	9.3 mg/dL	Calcium 13.8 mg/dL	Admitted to the hospital and treated with calcitonin, i.v. pamidronate and i.v. fluids. TPTD discontinued.
Hajime (2014)12	49, F	9.3 mg/dL	Calcium 10.4 mg/dL Phosphorus 0.9 mg/dL iPTH 6 pg/mL	Occurred two weeks after treatment initiation. TPTD was discontinued and calcium subsequently normalized.
Karatoprak (2012)14	47, F	9.3 mg/dL	Calcium 14.5 mg/dL Cr 2.24 mg/dL* iPTH 4.5 pg/mL	Occurred 7 months after TPTD start. Admitted to hospital with constipation, nausea, heartburn. Treated with i.v. fluids and furosemide. TPTD was discontinued and calcium subsequently normalized.
Ayasreh (2012)15	77, M	NA	Calcium 12.92 mg/dL Phosphorus 2.81 mg/dL Cr 2.5 mg/dL** iPTH 12.2 pg/mL 25(OH)D 19.8 ng/mL	One year after treatment start. Admitted to the hospital and treated with i.v. fluids, furosemide. TPTD was discontinued and calcium subsequently normalized.
Sistla (2019)16	74, F	NA	Calcium 17.3 mg/dL iPTH 3 ng/L	Admitted to the hospital with confusion and bone pain. Treated with i.v. fluids, i.v. bisphosphonates and calcitonin. TPTD was discontinued. Hypercalcemia persisted 3–4 weeks post-discharge.

Abbreviations: TPTD = teriparatide; iPTH = intact PTH; 25(OH)D = 25-hydroxy-vitamin D, Cr = creatinine, i.v = intravenous. Reference range: calcium 8.5–10.5 mg/dL, iPTH 10–65 pg/mL, 25-hydroxy vitamin D 30–100 ng/mL.

^*baseline creatinine 0.78 mg/dL;

^**baseline creatinine 1.18–1.37 mg/dL.